Primary progressive multiple sclerosis: Part of the MS disease spectrum or separate disease entity?

Acta Neuropathologica

Volumn 123, Issue 5, 2012, Pages 627-638

  Antel, Jack ^a   Antel, Samson ^b   Caramanos, Zografos ^b   Arnold, Douglas L ^b   Kuhlmann, Tanja ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Disease course; Imaging; Multiple sclerosis; Pathology

Indexed keywords

4 AMINOPYRIDINE; BETA INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; LAMOTRIGINE; METHOTREXATE; MITOXANTRONE; RILUZOLE; RITUXIMAB;

AXONAL INJURY; BRAIN DYSFUNCTION; COGNITIVE DEFECT; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; EVOKED VISUAL RESPONSE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEMIPLEGIA; HISTOPATHOLOGY; INFLAMMATION; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOGENESIS; PHENOTYPE; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REMYELINIZATION; REVIEW; SPASTIC PARESIS; T LYMPHOCYTE ACTIVATION; TWIN DISCORDANCE; VISUAL IMPAIRMENT;

BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 84862693197     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-012-0953-0     Document Type: Review

References (95)

1. Agosta F, Absinta M, Sormani MP et al (2007) In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 130:2211-2219 (Pubitemid 47236613)
2. Agosta F, Benedetti B, Rocca MA et al (2005) Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. Neurology 64:631-635 (Pubitemid 40261890)
3. Albert M, Antel J, Bruck W et al (2007) Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 17:129-138 (Pubitemid 46466131)
4. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV et al (2008) Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 40:1402-1403
5. Barkhof F, Bruck W, De Groot CJ et al (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60:1073-1081 (Pubitemid 36975794)
6. Bieniek M, Altmann DR, Davies GR et al (2006) Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 77:1036-1039 (Pubitemid 44338524)
7. Bjartmar C, Kinkel PR, Kidd G et al (2001) Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248-1252 (Pubitemid 32947384)
8. Booth DR, Heard RN, Stewart GJ et al (2010) Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. Nat Genet 42:469-470
9. Bramow S, Frischer JM, Lassmann H et al (2010) Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:2983-2998
10. Burwick RM, Ramsay PP, Haines JL et al (2006) APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 66:1373-1383 (Pubitemid 43739647)
11. Calabrese M, Battaglini M, Giorgio A et al (2010) Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 75:1234-1240
12. Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438-444
13. Caramanos Z, Narayanan S, Arnold DL (2005) 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 128:2483-2506 (Pubitemid 41552936)
14. Ceccarelli A, Rocca MA, Pagani E et al (2008) A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 42:315-322
15. Ceccarelli A, Rocca MA, Valsasina P et al (2009) A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Hum Brain Mapp 30:3009-3019
16. Chapman J, Vinokurov S, Achiron A et al (2001) APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 56:312-316 (Pubitemid 32144140)
17. Chataway J, Mander A, Robertson S et al (2001) Multiple sclerosis in sibling pairs: an analysis of 250 families. J Neurol Neurosurg Psychiatry 71:757-761 (Pubitemid 33121917)
18. Chen JT, Collins DL, Atkins HL et al (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63:254-262 (Pubitemid 351355304)
19. Chen JT, Kuhlmann T, Jansen GH et al (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36:1152-1158 (Pubitemid 47001724)
20. Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129:595-605 (Pubitemid 43278222)
21. De Stefano N, Matthews PM, Fu L et al (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-1477 (Pubitemid 28349900)
22. Dehmeshki J, Chard DT, Leary SM et al (2003) The normalappearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 250:67-74 (Pubitemid 36206687)
23. Di PC, Battaglini M, Stromillo ML et al (2008) Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Arch Neurol 65:236-243 (Pubitemid 351240787)
24. Dutta R, Chang A, Doud MK et al (2011) Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 69:445-454
25. Fisher E, Rudick RA, Cutter G et al (2000) Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6:373-377 (Pubitemid 32106796)
26. Frischer JM, Bramow S, Dal-Bianco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-1189
27. Ganter P, Prince C, Esiri MM (1999) Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 25:459-467 (Pubitemid 30045420)
28. Ge Y, Grossman RI, Udupa JK et al (2000) Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214:665-670 (Pubitemid 30115361)
29. Geurts JJ, Reuling IE, Vrenken H et al (2006) MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 55:478-483 (Pubitemid 43352544)
30. Gilmore CP, Donaldson I, Bo L et al (2009) Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 80:182-187
31. Goldschmidt T, Antel J, Konig FB et al (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72:1914-1921
32. Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494-502
33. Hawker K (2011) Progressive multiple sclerosis: characteristics and management. Neurol Clin 29:423-434
34. Hawker K, O'Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460-471
35. Hochmeister S, Grundtner R, Bauer J et al (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65:855-865 (Pubitemid 44371231)
36. Hohlfeld R (2004) Immunologic factors in primary progressive multiple sclerosis. Mult Scler 10(Suppl 1):S16-S21
37. Ingle GT, Stevenson VL, Miller DH et al (2003) Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126:2528-2536 (Pubitemid 37314440)
38. Inglese M, Ghezzi A, Bianchi S et al (2002) Irreversible disability and tissue loss in multiple sclerosis. A conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. Arch Neurol 59:250-255 (Pubitemid 34240941)
39. Inglese M, van Waesberghe JH, Rovaris M et al (2003) The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60:853-860 (Pubitemid 36297373)
40. Kapoor R, Furby J, Hayton T et al (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9:681-688
41. Khaleeli Z, Cercignani M, Audoin B et al (2007) Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 37:253-261 (Pubitemid 47068988)
42. Khaleeli Z, Ciccarelli O, Manfredonia F et al (2008) Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol 63:790-793 (Pubitemid 351945538)
43. Kidd D, Thorpe JW, Kendall BE et al (1996) MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 60:15-19 (Pubitemid 26012261)
44. Kremenchutzky M, Rice GP, Baskerville J et al (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129:584-594 (Pubitemid 43278221)
45. Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212
46. Kutzelnigg A, Faber-Rod JC, Bauer J et al (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17:38-44
47. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712 (Pubitemid 41552953)
48. Lassmann H (2008) The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 18:563-576 (ix)
49. Laule C, Vavasour IM, Zhao Y et al (2010) Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler 16:670-677
50. Leary SM, Davie CA, Parker GJM et al (1999) 1H magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis. J Neurol 246:1023-1026
51. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907-911 (Pubitemid 26134623)
52. Magliozzi R, Howell O, Vora A et al (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089-1104 (Pubitemid 47355604)
53. Magliozzi R, Howell OW, Reeves C et al (2010) A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68:477-493
54. Marshall J (1955) Spastic paraplegia of middle age; a clinicopathological study. Lancet 268:643-646
55. Martino G, Franklin RJ, Van Evercooren AB et al (2010) Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 6:247-255
56. McAlpine D (1972) Multiple sclerosis: a reappraisal. In: McAlpine D, Lumsden CE, Acheson ED (eds) Diagnosis and classification of multiple sclerosis, 2nd edn. Churchill Livingstone, Edinburgh
57. McDonald WI, Halliday AM (1977) Diagnosis and classification of multiple sclerosis. Br Med Bull 33:4-9
58. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919 (Pubitemid 47300005)
59. Mews I, Bergmann M, Bunkowski S et al (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 4:55-62 (Pubitemid 28197347)
60. Narayana PA, Wolinsky JS, Rao SB et al (2004) Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis. Mult Scler 10(Suppl 1):S73-S78 (Pubitemid 38807481)
61. Noseworthy JH, Lucchinetti C, Rodriguez M et al (2000) Multiple sclerosis. N Engl J Med 343:938-952
62. Oh J, Pelletier D, Nelson SJ (2004) Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch Neurol 61:1081-1086 (Pubitemid 38915950)
63. Patani R, Balaratnam M, Vora A et al (2007) Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 33:277-287 (Pubitemid 46701044)
64. Patrikios P, Stadelmann C, Kutzelnigg A et al (2006) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165-3172 (Pubitemid 44871433)
65. Penny S, Khaleeli Z, Cipolotti L et al (2010) Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis. Neurology 74:545-552
66. Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292-302
67. Prineas JW, Connell F (1979) Remyelination in multiple sclerosis. Ann Neurol 5:22-31 (Pubitemid 9083248)
68. Quintana FJ, Farez MF, Viglietta V et al (2008) Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 105:18889-18894
69. Ramio-Torrenta L, Sastre-Garriga J, Ingle GT et al (2006) Abnormalities in normal-appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry 77:40-45 (Pubitemid 43022688)
70. Revesz T, Kidd D, Thompson AJ et al (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759-765 (Pubitemid 24281838)
71. Rovaris M, Gallo A, Falini A et al (2005) Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 62:898-902 (Pubitemid 40973451)
72. Rovaris M, Gallo A, Valsasina P et al (2005) Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage 24:1139-1146 (Pubitemid 40164515)
73. Rovaris M, Judica E, Sastre-Garriga J et al (2008) Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 14:455-464 (Pubitemid 351943857)
74. Sastre-Garriga J, Ingle GT, Chard DT et al (2005) Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128:1454-1460 (Pubitemid 40826197)
75. Sastre-Garriga J, Ingle GT, Chard DT et al (2004) Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 22:353-359 (Pubitemid 38515842)
76. Sastre-Garriga J, Ingle GT, Rovaris M et al (2005) Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 65:633-635 (Pubitemid 41170733)
77. Sawcer S, Hellenthal G, Pirinen M et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219
78. Sepulcre J, Sastre-Garriga J, Cercignani M et al (2006) Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 63:1175-1180 (Pubitemid 44232328)
79. Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174 (Pubitemid 38656388)
80. Smith KJ (1994) Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye 8:224-237 (Pubitemid 24189832)
81. Stevenson VL, Miller DH, Rovaris M et al (1999) Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 52:839-845 (Pubitemid 29120193)
82. Suhy J, Rooney WD, Goodkin DE et al (2000) 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6:148-155 (Pubitemid 30392111)
83. Tallantyre EC, Bo L, Al-Rawashdeh O et al (2009) Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132:1190-1199
84. Tallantyre EC, Bo L, Al-Rawashdeh O et al (2010) Clinicopathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 16:406-411
85. Thompson AJ, Kermode AG, MacManus DG et al (1990) Patterns of disease activity in mutliple sclerosis: clinical and magnetic resonance imaging study. Br Med J 300:631-634 (Pubitemid 20107324)
86. Thompson AJ, Kermode AG, Wicks D et al (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53-62
87. Thompson AJ, Montalban X, Barkhof F et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831-835 (Pubitemid 30390209)
88. Tur C, Penny S, Khaleeli Z et al (2011) Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis. Mult Scler 17(11):1324-1332
89. Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10:649-656
90. Ukkonen M, Dastidar P, Heinonen T et al (2003) Volumetric quantitation by MRI in primary progressive multiple sclerosis: volumes of plaques and atrophy correlated with neurological disability. Eur J Neurol 10:663-669 (Pubitemid 38030876)
91. Vrenken H, Barkhof F, Uitdehaag BM et al (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256-266 (Pubitemid 40171039)
92. Vrenken H, Geurts JJ (2007) Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. Expert Rev Neurother 7:271-279 (Pubitemid 46434175)
93. Wegner C, Esiri MM, Chance SA et al (2006) Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67:960-967 (Pubitemid 44454585)
94. Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133-146 (Pubitemid 19056478)
95. Wolinsky JS (2004) The PROMiSe trial: baseline data review and progress report. Mult Scler 10(Suppl 1):S65-S71